As to the biological effect of the mutations, we detected a modest but statistically significant decrease in neutrophils in the MS patients with mutations vs. non-carriers, consistent with reports of neutropenia in STAT3 mutation related T-LGL leukemia and Felty syndrome [24, 25]. The gene discussed is STAT3; the disease is myeloid sarcoma.